

Misonix Enlists Partnermed to Distribute Market Leading Sonablate(R) 500 HIFU Prostate Cancer Treatment Device in Northern Europe

Norway and Sweden Increase European Presence to 16 Nations where

SB500 for Visually Directed HIFU is Available

FARMINGDALE, N.Y.--(BUSINESS WIRE)--March 6, 2007--Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that it has further expanded its European business of High Intensity Focused Ultrasound ("HIFU") using the Sonablate(R) 500 ("SB500") for prostate cancer treatment through a distribution agreement with Partnermed AS for the SB500 in the Northern European countries of Norway and Sweden. With the entry into these two new countries, Misonix has further extended its lead as the most widely available HIFU prostate cancer treatment in Europe.

The SB500 is a medical device developed by Focus Surgery, Inc. and manufactured by Misonix. Misonix also has the exclusive European distribution rights for the product. Misonix is an investor in privately-held Focus Surgery, one of the most prominent developers of HIFU in the world.

Established in 2004, Partnermed AS markets medical technology products throughout Norway and Sweden. The principals at Partnermed collectively have more than 50 years experience in the industry. The company's product portfolio includes a broad range of medical capital equipment with particular expertise and concentration in the field of urology where they also distribute for products for Laserscope and Stonelight, among other manufacturers.

"In our mission to bring the most advanced and efficacious ultrasonic medical treatments to the benefit of the worldwide healthcare community, our entry into Norway and Sweden with the Sonablate 500 for HIFU treatment of kidney cancer is an important step," stated Michael A. McManus, Jr., President and CEO of Misonix. "These two countries rank second and third, respectively, among the top nations in the world in prostate cancer death rates according to the National Prostate Cancer Coalition in 2006. We are pleased to be working with Partnermed AS in fighting prostate cancer and believe that given their intimate knowledge of two nations of significance we can make a lasting difference."

Integral to the success to date for Misonix and the SB500 in Europe is the results of a previously announced study. This study reported that 84% of patients were able to achieve success as measured by PSA nadir levels dropping to 0.2ng/ml or less after treatment. This measurement for success using the SB500 has not been achieved by previous published HIFU techniques; these PSA nadirs are typically associated with a surgical approach.

According to the Comprehensive Cancer Monitoring Program in Europe, there are over 200,000 new cases of prostate cancer on the continent annually, creating a tremendous opportunity for Misonix. The European market is estimated to be the approximate equivalent of that in the United States. HIFU treatment using the SB500 is an approved procedure in most European countries. Including Norway and Sweden, the procedure is now available in 16 European countries, and to date over 4,000 SB500 treatments have been completed worldwide.

About Misonix:

Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of \$3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

CONTACT: Misonix
Richard Zaremba, 631-694-9555
Chief Financial Officer
invest@misonix.com
or
Investor Relations:
Darrow Associates, Inc.
Jordan M. Darrow, 631-367-1866
jdarrow@darrowir.com

SOURCE: Misonix, Inc.